Platelet Production and Kinetics in HIV-Infected Patients With Thrombocytopenia
| . | Normal Controls (no.) . | HIV Patients (6) . | #1 . | #2 . | #3 . | #4 . | #5 . | #6 . |
|---|---|---|---|---|---|---|---|---|
| Platelet Formation | ||||||||
| Platelet count (×103/μL) | 250 ± 40 (98) | 46 ± 43 | 102 | 5 | 25 | 8 | 98 | 39 |
| P < 10−4 | ||||||||
| MPV (fL) | 9.5 ± 1.7 (98) | 10.5 ± 2.0 | 8.7 | 13.7 | 11.2 | 10.7 | 8 | 10.9 |
| P > 0.3 | ||||||||
| Antiplatelet gpIIIa49-66 antibodies (arbitrary OD units) | ≤21 (20) | 129 ± 91 P < .001 | 266 | 188 | 60 | 169 | 27 | 65 |
| Recovery (%) | 65 ± 5 (20) | 33 ± 16 | 64 | 23 | 23 | 24 | 29 | 35.5 |
| P < 10−4 | ||||||||
| Platelet life span (h) | 232 ± 38 (20) | 87 ± 39 | 115 | 69 | 101 | 16.5 | 108 | 115 |
| P < 10−4 | ||||||||
| Platelet mass turnover (×105 fL/μL/d) | 3.8 ± 0.4 (20) | 3.8 ± 1.5 | 2.9 | 3.1 | 2.9 | 5.3 | 6 | 2.5 |
| P > 0.5 | ||||||||
| Thrombopoietic stimulus | ||||||||
| Serum endogenous TPO (pg/mL) | 95 ± 6 (98) | 596 ± 471 | 535 | 330 | 170 | 390 | 212 | 1900 |
| P < 10−3 | ||||||||
| Platelet TPO receptors (per platelet) | 207 ± 99 (9) | 461 ± 259 | 645 | 594 | 809 | 333 | 183 | 200 |
| P = .04 | ||||||||
| Megakaryocytopoiesis | ||||||||
| Megakaryocyte number (×106/kg) | 11 ± 2.1 (20) | 30 ± 15 | 14.6 | 31.8 | 8.5 | 48.8 | 36 | 37.6 |
| P = .02 | ||||||||
| Megakaryocyte vol (×103 fL) | 28 ± 4.5 (20) | 32 ± 0.9 | 32.2 | 30.3 | 32.5 | 31.5 | 31.9 | 31.9 |
| P = .05 | ||||||||
| Megakaryocyte Progenitors (megas/1,000 CD34+ cells) | 27 (9) | 3.3 P = .02 | 1.1 | 2.7 | 5.1 | 3.8 | 0.4 | 7.3 |
| Megakaryocyte mass (×1010 fL/kg) | 31 ± 5.3 (20) | 93 ± 47 | 47 | 96.4 | 27.6 | 154 | 115 | 119 |
| P = .007 |
| . | Normal Controls (no.) . | HIV Patients (6) . | #1 . | #2 . | #3 . | #4 . | #5 . | #6 . |
|---|---|---|---|---|---|---|---|---|
| Platelet Formation | ||||||||
| Platelet count (×103/μL) | 250 ± 40 (98) | 46 ± 43 | 102 | 5 | 25 | 8 | 98 | 39 |
| P < 10−4 | ||||||||
| MPV (fL) | 9.5 ± 1.7 (98) | 10.5 ± 2.0 | 8.7 | 13.7 | 11.2 | 10.7 | 8 | 10.9 |
| P > 0.3 | ||||||||
| Antiplatelet gpIIIa49-66 antibodies (arbitrary OD units) | ≤21 (20) | 129 ± 91 P < .001 | 266 | 188 | 60 | 169 | 27 | 65 |
| Recovery (%) | 65 ± 5 (20) | 33 ± 16 | 64 | 23 | 23 | 24 | 29 | 35.5 |
| P < 10−4 | ||||||||
| Platelet life span (h) | 232 ± 38 (20) | 87 ± 39 | 115 | 69 | 101 | 16.5 | 108 | 115 |
| P < 10−4 | ||||||||
| Platelet mass turnover (×105 fL/μL/d) | 3.8 ± 0.4 (20) | 3.8 ± 1.5 | 2.9 | 3.1 | 2.9 | 5.3 | 6 | 2.5 |
| P > 0.5 | ||||||||
| Thrombopoietic stimulus | ||||||||
| Serum endogenous TPO (pg/mL) | 95 ± 6 (98) | 596 ± 471 | 535 | 330 | 170 | 390 | 212 | 1900 |
| P < 10−3 | ||||||||
| Platelet TPO receptors (per platelet) | 207 ± 99 (9) | 461 ± 259 | 645 | 594 | 809 | 333 | 183 | 200 |
| P = .04 | ||||||||
| Megakaryocytopoiesis | ||||||||
| Megakaryocyte number (×106/kg) | 11 ± 2.1 (20) | 30 ± 15 | 14.6 | 31.8 | 8.5 | 48.8 | 36 | 37.6 |
| P = .02 | ||||||||
| Megakaryocyte vol (×103 fL) | 28 ± 4.5 (20) | 32 ± 0.9 | 32.2 | 30.3 | 32.5 | 31.5 | 31.9 | 31.9 |
| P = .05 | ||||||||
| Megakaryocyte Progenitors (megas/1,000 CD34+ cells) | 27 (9) | 3.3 P = .02 | 1.1 | 2.7 | 5.1 | 3.8 | 0.4 | 7.3 |
| Megakaryocyte mass (×1010 fL/kg) | 31 ± 5.3 (20) | 93 ± 47 | 47 | 96.4 | 27.6 | 154 | 115 | 119 |
| P = .007 |